Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

    NEXT STORY
    Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
    PREV STORY
    Digital Radiography Market to Reach US$ 2,978.3 Mn by 2026, FDA Clearance to Philips and Other Companies to Enable Growth, says Fortune Business Insights
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients

    Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially ...

    author_avatar
    NASDAQ Market News

    Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility

    SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced ...

    author_avatar
    NASDAQ Market News

    R1 RCM Reports Third Quarter 2018 Results

    CHICAGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading ...

    author_avatar
    NASDAQ Market News